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Objectives The purpose of this study was to examine the association between hyperglycemia and subclinical myocardial
injury in persons without clinically evident coronary heart disease (CHD).
Background Hyperglycemia is associated with an increased risk of cardiac events, but limited information is available on its
relationship to subclinical myocardial damage. Elevated cardiac troponin T even below traditional detection lev-
els can be detected by a novel high-sensitivity assay.
Methods We examined the association between baseline glycated hemoglobin (HbA1c) and high-sensitivity cardiac tro-
ponin T (hs-cTnT) in 9,661 participants free of CHD and heart failure in the ARIC (Atherosclerosis Risk in Com-
munities) study. Multivariable logistic regression models characterized the association between clinical catego-
ries of HbA1c (5.7%, 5.7% to 6.4%, and 6.5%) and our primary outcome of elevated hs-cTnT (14 ng/l).
Results Higher baseline values of HbA1c were associated in a graded fashion with elevated hs-cTnT (p for trend 
0.001). After adjusting for traditional risk factors, compared to persons with HbA1c 5.7%, the odds ratios of
elevated hs-cTnT for persons with HbA1c 5.7% to 6.4% and 6.5% were 1.26 (95% confidence interval: 1.01 to
1.56) and 1.97 (95% confidence interval: 1.44 to 2.70), respectively.
Conclusions Higher HbA1c is associated with elevated hs-cTnT among persons without clinically evident CHD, suggesting that
hyperglycemia contributes to myocardial injury beyond its effects on development of clinical atherosclerotic cor-
onary disease. (J Am Coll Cardiol 2012;59:484–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.875Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality among persons with diabetes mel-
litus (1). Although the excess cardiovascular risk observed in
dysglycemic states has been partially explained by coexisting
cardiovascular risk factors (e.g., obesity and hypertension),
there is strong evidence supporting hyperglycemia, even
below the threshold of diabetes, as an independent risk
factor for coronary heart disease (CHD) morbidity and
mortality (2). Glycated hemoglobin (HbA1c), a marker of
chronic hyperglycemia, is associated with incident CHD
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recommended as a diagnostic test for diabetes mellitus (7).
Much less is known about the association of chronic
hyperglycemia with subclinical CHD. A small number of
studies have used imaging techniques to examine the cross-
sectional relationship of HbA1c with subclinical atherosclerosis
(8,9). There is limited information on the relationship between
hyperglycemia and subclinical myocardial injury at earlier
stages, before it can be detected by imaging modalities.
See page 490
Newly identified biomarkers allow for the noninvasive
identification of subclinical myocardial damage (10). Car-
diac troponin-T (cTnT) has been independently associated
with CHD (11,12). A novel high-sensitivity cardiac
troponin-T (hs-cTnT) assay allows for the detection of
hs-cTnT levels below clinical thresholds or detection levels
of earlier assays. Using this novel assay, troponin levels
below the conventional limit of detection have recently been
shown to predict cardiovascular events and death in persons
with congestive heart failure (CHF) (13), CHD (14), and in
the general population (15–17). Some have suggested that
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January 31, 2012:484–9 HbA1c and Myocardial Injuryminimally elevated troponin levels may represent subclinical
cardiac injury (18,19) and hs-cTnT may now allow for the
identification of previously undetected early stages of myo-
cardial injury.
The objective of this study was to test the hypothesis that
in persons without clinically evident CHD or heart failure,
chronic hyperglycemia—assessed by HbA1c—would be in-
dependently associated with subclinical myocardial injury
measured by elevated hs-cTnT.
Methods
More detailed methods are described in the online Supple-
ment. Briefly, we explored the association between catego-
ries of HbA1c and hs-cTnT in participants without CHD
in the ARIC (Atherosclerosis Risk in Communities) study.
The cTnT was measured using a novel high-sensitivity
assay, Elecsys Troponin T (Roche Diagnostics, Indianapo-
lis, Indiana) with a lower limit of detection of 3.0 ng/l.
Elevated hs-cTnT was defined as levels above the previously
reported 99th percentile value (14 ng/l) in a healthy sub-
population ages 20 to 70 years.
Statistical analysis. The HbA1c was modeled as a con-
tinuous variable and by clinical categories: 5.7%, 5.7%
o 6.4%, and 6.5% (7), and baseline characteristics were
ompared across these categories. Linear splines (with
nots at clinical cut-points) were used to characterize the
hape of the association between HbA1c and hs-cTnT
nd multivariable logistic regression to assess the associ-
tion between categories of HbA1c and elevated hs-cTnT
14.0 ng/l). For continuous models, undetectable levels
f hs-cTnT were assigned a value of 1.5 ng/l (i.e.,
ne-half the lower limit of detection). In participants
ho fasted 8 h at the time of visit 2 (n  9,550), we
evaluated the association of categories of fasting glucose:
100 mg/dl, 100 to 125 mg/dl, and 126 mg/dl, with
elevated hs-cTnT.
We implemented 4 models for the adjustment of covari-
ates: model 1 unadjusted; model 2 adjusted for age, sex and
race; model 3 adjusted for field center, body mass index,
education, systolic and diastolic blood pressures, smoking,
low-density lipoprotein and high-density lipoprotein cho-
lesterol, alcohol, hypertension medication, left ventricular
hypertrophy, history of diabetes, and estimated glomerular
filtration rate; and model 4a adjusted for fasting glucose and
model 4b adjusted for HbA1c.
Sensitivity analyses excluded persons with atrial fibrilla-
tion, estimated glomerular filtration rate 60 ml/min/1.73
m2 or stroke, before or at visit 4. We also excluded persons
with incident CHD up to 6 months after hs-cTnT samples
were obtained. We tested for interaction with age, race, and
sex. Analyses were conducted using STATA 11.1 (Stata-
Corp., College Station, Texas), and a p value of  0.05 was
statistically significant. aResults
Mean age was 56.6 years, and
58.9% were female (Table 1).
Participants with higher HbA1c
were more likely to be African
American, hypertensive, and
have higher body mass index and
low-density lipoprotein choles-
terol, and lower high-density li-
poprotein cholesterol. A total of
6,400 subjects (66.3%) had de-
tectable levels of hs-cTnT. In
persons with and without a his-
tory of diagnosed diabetes, the
corresponding percentages were
81.9% and 65.2%.
Baseline HbA1c was positively associated with hs-cTnT
in a linear fashion (tests for differences in the slope at
clinical cut-points of HbA1c were not significant) (Fig. 1).
Compared to persons with HbA1c 5.7%, hs-cTnT values
were 25% higher in persons with HbA1c 5.7% to 6.4%
and 70% higher among participants with HbA1c 6.5%.
In fully adjusted models, every 1-percentage point higher
HbA1c value was associated with a 0.7 ng/l higher value of
hs-cTnT (95% confidence interval [CI]: 0.5 to 1.0; p 
0.001).
Overall, 7.3% of participants had elevated hs-cTnT (14
ng/l). In persons with and without diabetes, the correspond-
ing percentages were 21.8% and 6.3%. In this population of
persons without clinically evident CHD or heart failure, the
99th percentile of hs-cTnT was 30 ng/l. The corresponding
99th percentiles were 27 ng/l and 54 ng/l for persons
without and with a history of diabetes, respectively. Increas-
ing HbA1c categories were associated in a graded fashion
with elevated hs-cTnT (Fig. 2). In analysis adjusted for age,
sex, and race, the percentage of persons with elevated
hs-cTnT among persons with a HbA1c 5.7%, 5.7% to
6.4%, and 6.5% was 3.8%, 5.7%, and 14.0%, respectively.
Compared to persons with HbA1c 5.7%, higher
HbA1c values were strongly associated with elevated hs-
cTnT (Table 2). In age, race, and sex adjusted analyses,
increasing HbA1c categories was significantly associated
with elevated hs-cTnT for HbA1c of 5.7% to 6.4% (odds
ratio [OR]: 1.51; 95% CI: 1.23 to 1.85) and for HbA1c
6.5% (OR: 4.09; 95% CI: 3.25 to 5.15). After adjusting
for other cardiovascular risk factors, the association was
attenuated but remained significant. This association was
unaltered by further adjustment for fasting glucose (Table 2,
Model 4a). Analysis performed stratified by previously
diagnosed diabetes demonstrated a similar association (On-
line Table 1). Excluding participants with estimated glo-
merular filtration rate 60 ml/min/1.73 m2, stroke, atrial
brillation before or at visit 4, and persons with incident
HD within 6 months after hs-cTnT measurement did not
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CHF  congestive heart
failure
CVD  cardiovascular
disease
HbA1c  glycated
hemoglobin
hs-cTnT  high-sensitivity
cardiac troponin-T
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persons with a fasting glucose 100 mg/dl, higher fasting
lucose levels were associated with elevated hs-cTnT (OR
or glucose126 mg/dl: 2.93, 95% CI: 2.30 to 3.75) (Table 3).
his association was no longer significant after adjusting for
dditional cardiovascular risk factors or after further adjust-
ent for HbA1c (Table 3, Model 4b).
Baseline Characteristics by Clinical CategoriesTable 1 Baseline Characteristics by Clinica
Characteristic
Total
(n  9,661)
Glycated hemoglobin, % 5.4 (5.2–5.8)
Fasting glucose, mg/dl 109.7 34.8
Age, yrs 56.6 5.6
Female, % 58.9
African American, % 22.0
LDL-cholesterol, mg/dl 132.2 35.9
HDL-cholesterol, mg/dl 50.9 16.7
Body mass index, kg/m2* 27.8 5.3
eGFR, ml/min/1.73 m2 85.7 17.8
Hypertension, % 31.3
History of diabetes, % 6.3
Left ventricular hypertrophy,† % 1.7
Education, %
Less than high school 18.1
High school or equivalent 42.4
College or above 39.5
Alcohol use, %
Current 58.9
Former 18.5
Never 22.6
Smoking status, %
Current 19.1
Former 37.6
Never 43.3
Values are median (25th to 75th percentiles), mean  SD, or proport
of the height in meters. †Left ventricular hypertrophy calculated by el
eGFR  estimated glomerular filtration rate; LDL  low-density lipo
Figure 1 Linear Spline Models
Plotted values using linear spline models with knots at glycated hemoglobin
(HbA1c) of 5.7% and 6.5%. Adjusted for age, sex, and race, and truncated at
HbA1c of 13%. Shaded areas represent 95% confidence intervals.There was no interaction between HbA1c and sex or
ace for elevated hs-cTnT (p  0.110 for both). There
as evidence that age may modify the association be-
ween HbA1c and elevated hs-cTnT (p for interaction 
ycated Hemoglobingories of Glycated Hemoglobin
<5.7%
 7,169)
5.7%–6.4%
(n  1,729)
>6.5%
(n  763)
3 (5.1–6.5) 5.9 (5.8–6.1) 7.5 (6.8–9.5)
0.6 10.4 111.3 16.6 191.7 76.4
6.3 5.6 57.6 5.6 57.5 5.7
59.3 56.0 62.4
14.5 40.7 49.8
0.5 35.3 137.0 36.7 137.7 37.9
2.3 17.0 48.1 14.9 44.8 14.0
7.0 4.7 29.3 5.8 31.8 5.9
4.7 16.8 87.6 19.5 90.7 21.2
26.2 41.5 56.1
1.1 5.6 56.5
1.1 3.2 3.6
14.3 27.1 33.3
43.6 39.6 37.2
42.1 33.3 29.5
63.7 48.8 36.2
15.5 25.4 31.2
20.8 25.8 32.6
17.6 25.4 18.1
38.0 36.1 36.4
44.3 38.4 45.5
he body-mass index is the weight in kilograms divided by the square
rdiographic Cornell criteria.
; HDL  high-density lipoprotein.
Figure 2 Percentage of Subjects With Elevated hs-cTnT,
by HbA1c Category
Percentage and 95% confidence intervals of subjects with elevated high-sensi-
tivity cardiac troponin-T (hs-cTnT), by category of glycated hemoglobin (HbA1c).
Adjusted for age, sex, and race.of Gll Cate
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January 31, 2012:484–9 HbA1c and Myocardial Injury0.048). When stratified by median age (56 years), com-
pared to persons with HbA1c 5.7%, HbA1c 6.5% was
more strongly associated with elevated hs-cTnT among
younger persons (OR: 2.13; 95% CI: 1.23 to 3.69) than
among older ones (OR: 1.88; 95% CI: 1.28 to 2.76).
Discussion
In a community-based population of almost 10,000 subjects
without clinically evident CHD, chronic hyperglycemia was
independently associated with subclinical myocardial injury,
as assessed by elevated levels of hs-cTnT in both persons
with and without diabetes.
Elevated troponin levels have been previously associated
with cardiovascular events (11). Using conventional assays,
troponin can be detected in 0.7% of the population (20) and
is associated with myocardial infarction and death (11). In
contrast, the novel high-sensitivity troponin assay allows for
the detection of troponin at levels far below previous
detection limits. We observed that hs-cTnT was present in
66.3% of the ARIC study population without clinically
evident CHD. The 99th percentile value for hs-cTnT in our
study (30 ng/l) was considerably higher than that reported
by the manufacturer (14 ng/l) in a healthy population ages
20 to 70 years. Firm reference ranges for this assay have not
yet been established.
Others have recently shown in both the ARIC study (17)
and in other cohorts (15,16) that troponin levels measured
with the highly sensitive assay independently predict car-
diovascular events. In the ARIC study, hs-cTnT levels
above the 99th percentile were associated with all-cause
mortality (OR: 3.69, 95% CI: 3.21 to 4.88) (17). Also of
Odds Ratios (95% CI) for Elevated hs-TnT by Clinical Categories ofTable 2 Odds Ratios (95% CI) for Elevated hs-TnT by Clinical C
HbA1c Category
Model 1 Mo
OR (95% CI) OR
5.7% (Reference) 1.00 (Reference) 1.00
5.7% to 6.4% 1.91 1.58–2.30 1.51
6.5% 4.30 3.50–5.29 4.09
p value for trend overall 0.001 0.001
Model 1 unadjusted. Model 2 adjusted for age, race, and sex. Model 3model 2 plus field ce
and high-density lipoprotein cholesterol, alcohol use, hypertension medication use, estimated
Model 4a  model 3 plus fasting glucose concentration.
CI  confidence interval; HbA1c  glycated hemoglobin; hs-TnT  highly sensitive troponin T; O
Odds Ratios (95% CI) for Elevated hs-TnT by Clinical Categories ofTable 3 Odds Ratios (95% CI) for Elevated hs-TnT by Clinical C
Glucose Category
Model 1 M
OR (95% CI) OR
100 mg/dl (Reference) 1.00 1.00
100 to 126 mg/dl 1.64 1.36–1.97 1.17
126 mg/dl 3.99 3.17–5.03 2.93
p value for trend 0.001 0.001
Model 1 unadjusted. Model 2 adjusted for age, race, and sex. Model 3model 2 plus field ce
and high-density lipoprotein cholesterol, alcohol use, hypertension medication use, estimated
Model 4b  model 3 plus glycated hemoglobin.
Abbreviations as in Table 2.interest, minimally elevated levels of hs-cTnT (3 to 5 ng/l)
were associated with all-cause mortality (OR: 1.37, 95% CI:
1.14 to 1.65).
Numerous studies have demonstrated associations be-
tween hyperglycemia and macrovascular and microvascu-
lar complications (2– 4,6). The use of this high sensitivity
assay allowed for the detection of minimally elevated
troponin levels thought to represent subclinical cardiac injury
(18–20). Although hyperglycemia is traditionally thought to
be associated with cardiovascular events through atheroscle-
rosis, our results suggest that hyperglycemia may contribute
to cardiovascular events by alternate mechanisms.
A potential mechanism by which hyperglycemia in-
duces myocardial injury is hyperglycemia-mediated cor-
onary microvascular dysfunction (21,22). Other mecha-
nisms include oxidative stress (21), advanced glycation
end-products (23,24), and myocardial fibrosis (25). Dia-
betic subjects have increased oxidative stress (26), and
administration of antioxidant vitamin C has been shown
to improve endothelial dysfunction in diabetic patients
(27). Finally, hyperglycemia may also be associated with
myocardial damage through silent atherosclerotic disease
and, as others have shown, as many as 12% of asymp-
tomatic diabetic subjects had coronary artery stenosis
75% (28).
Although some have demonstrated associations of hyper-
glycemia with subclinical CVD using imaging modalities
(8,9), we have demonstrated an association between hyper-
glycemia and early subclinical myocardial injury. Recent
studies using this new highly sensitive assay for cTnT
suggest that the association with cardiac outcomes is medi-
cories of HbA1c
Model 3 Model 4a
95% CI) OR (95% CI) OR (95% CI)
eference) 1.00 (Reference) 1.00 (Reference)
23–1.85 1.26 1.01–1.56 1.23 0.99–1.53
25–5.15 1.97 1.44–2.70 1.70 1.17–2.46
0.001 0.003
dy mass index, education, systolic and diastolic blood pressures, smoking, low-density lipoprotein
rular filtration rate, left ventricular hypertrophy, and history of diagnosed diabetes mellitus.
ds ratio.
oseories of Glucose
2 Model 3 Model 4b
(95% CI) OR (95% CI) OR (95% CI)
1.00 1.00
0.96–1.42 0.95 0.78–1.16 0.91 0.74–1.11
2.30–3.75 1.30 0.95–1.78 0.88 0.62–1.25
0.075 0.501
dy mass index, education, systolic and diastolic blood pressures, smoking, low-density lipoprotein
rular filtration rate, left ventricular hypertrophy, and history of diagnosed diabetes mellitus.HbA1ateg
del 2
(
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While left ventricular mass was independently associated
with detectable levels of hs-cTnT, coronary artery calci-
um—a marker of coronary atherosclerosis—was not (16).
The hs-cTnT had a stronger association with total mortality
and heart failure than with CHD (17). Furthermore, the
association with nonfatal CHD was even weaker than for
fatal CHD, again suggesting that hs-cTnT is related to
outcomes by mechanisms other than atherosclerosis. Nev-
ertheless, because of the observational nature of these
investigations, the mechanisms remain unclear.
Our results suggest that HbA1c performs better as a
marker of subclinical myocardial damage compared to
fasting glucose and are consistent with the growing body of
literature demonstrating that HbA1c is an important
marker of cardiovascular risk (4). Our data support new
recommendations for the use of HbA1c for the diagnosis of
diabetes and identification of persons at high risk for
development of complications (7).
Study limitations. Measurements of HbA1c and hs-cTnT
were not available at the same visit. Although in sensitivity
analysis we excluded persons with any history of clinical
CHD at visit 4 and incident CHD in the 6 months after
hs-cTnT measurement, we cannot rule out the possibility
that a number of subjects had elevated troponin levels at the
baseline visit. Although elevated hs-cTnT levels have now
been associated with increased CVD (15–17), whether clinical
management should be modified on the basis of chronically
elevated levels of troponin is unknown. Because we excluded
persons who died or had CHD between visit 2 and visit 4 and
because HbA1c is associated with both elevated troponin levels
and mortality, there is a possibility that this resulted in selection
bias. That would tend to underestimate the true association.
Although we adjusted for known risk factors for CHD, we
cannot exclude the possibility of residual confounding in this
observational study. There were 679 people excluded from our
analysis (10% of the study sample) due to missing data.
Nonetheless, this study represents one of the largest
community-based studies of HbA1c and hs-cTnT. Additional
major strengths of this study include the large sample of
persons with and without diabetes, including a large number of
African Americans, rigorous measurement of cardiovascular
risk factors, and our ability to exclude clinical CHD cases
utilizing comprehensive and adjudicated surveillance data for
clinical events.
Conclusions
In this community-based study of persons without clinically
evident CHD, HbA1c was associated with hs-cTnT in a
graded fashion. Our findings suggest that hyperglycemia con-
tributes to myocardial injury beyond its effects on the develop-
ment of clinical atherosclerotic coronary disease.Reprint requests and correspondence: Dr. Elizabeth Selvin,
Johns Hopkins Bloomberg School of Public Health, 2024 East
Monument Street, 2-600, Baltimore, Maryland 21205. E-mail:
lselvin@jhsph.edu.
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